The Rocky Mount, N.C., plant is responsible for manufacturing more than 25 percent of Pfizer’s injectable drugs including anesthesia, analgesia, therapeutics, anti-infectives and neuromuscular blockers.
Now that production has resumed, the company stated that manufacturing of another, new injectable, R3, is also beginning.
“There are approximately 13 medicines in production on the lines that have restarted, including products that are currently available through Pfizer’s emergency ordering process,” Pfizer’s news release states. “The first shipments of these medicines to distribution centers are anticipated in the fourth quarter of 2023. While manufacturing has resumed, it is important to note that some medicines may not be back in full supply until next year.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.